SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.

Already have an account? Log in here
RETURN TO HOME
$0
Autologous, CAR-T, CD19

The Race to 2L DLBCL: Breyanzi’s Ph3 TRANSFORM Trial vs Yescarta’s Ph3 ZUMA-7 Study; Can BMS Shift Toward Outpatient CD19 CAR-T Administration? ASH 2021 Day 1 Part 2

Here is a brief preview of this blast: On the first and second day of ASH 2021, 4 clinical updates were presented by BMS and Gilead (Kite) including Breyanzi’s (CD19 CAR-T) and Yescarta’s (CD19 CAR-T) efficacy and safety profiles in 2L DLBCL. Moreover, BMS commented on the feasibility of administering Breyanzi in the outpatient setting. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.